Pharmaceutical

Coya stretches lead drug’s development to Parkinson’s and dementia

Coya plans to file investigational new drug applications for COYA 302 in amyotrophic lateral sclerosis and frontotemporal dementia later this year.

Jan 17, 2024 - 18:00
Coya stretches lead drug’s development to Parkinson’s and dementia
Coya plans to file investigational new drug applications for COYA 302 in amyotrophic lateral sclerosis and frontotemporal dementia later this year.
Read the original article

Tags:

Previous Article

Bupa is leveraging its unique position to develop IoT and AI features

Next Article

US PTO voids Seagen’s ADC patent infringement claims against Daiichi

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A letter from the executive editor: STAT’s investigation into a UnitedHealth algorithm

A letter from the executive editor: STAT’s investigatio...

Nov 15, 2023

STAT+: Massachusetts biotechs seek to piggyback on weight loss drug boom

STAT+: Massachusetts biotechs seek to piggyback on weig...

Oct 24, 2023

A new algorithm unveils CRISPR ‘treasure trove’

A new algorithm unveils CRISPR ‘treasure trove’

Nov 27, 2023